Prediction of response to docetaxel by immunohistochemical analysis of CYP3A4 expression in human breast cancers

[1] Seidman AD(1993)Phase II evaluation of Taxotere (RP56976 NSC 628503) as initial chemotherapy for metastatic breast cancer Proc Am Soc Clin Oncol 12 63-63

[2] Hudis C(1994)A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the ORTC Early Clinical Trials Group Ann Oncol 5 527-532

[3] Crown JPA(1994)Phase II evaluation of Taxotere (RP56976) as chemotherapy for anthracycline refractory metastatic breast cancer (abstract 512) In: 8th NCI-EORTC Symp on New Drugs in Cancer Therapy: 1994 Ann Oncol 5 203-203

[4] Ten Bokkel Huinink WW(1994)Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers Eur J of Cancer 30A 1002-1007

[5] Prove AM(2001)Prediction of chemotherapeutic response by Technetium 99m-MIBI scintigraphy in breast carcinoma patients Cancer 92 232-239

[6] Piccart M(1997)Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes J Clin Invest 100 1282-1293

[7] Steward W(1994)Partial synthesis of major human metabolites of decetaxel Tetrahedron 50 10289-10298

[8] Tursz T(2002)Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues Int J Cancer 97 129-132

[9] Wanders J(1999)MGMT- and P450 3A-inhibitors do not sensitize glioblastoma cell cultures against nitrosoureas Clin Neuropathol 18 1-8

[10] Ravdin PM(1999)Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice Clin Cancer Res 5 883-889

[1] Seidman AD(1993)Phase II evaluation of Taxotere (RP56976 NSC 628503) as initial chemotherapy for metastatic breast cancer Proc Am Soc Clin Oncol 12 63-63

[2] Hudis C(1994)A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the ORTC Early Clinical Trials Group Ann Oncol 5 527-532

[3] Crown JPA(1994)Phase II evaluation of Taxotere (RP56976) as chemotherapy for anthracycline refractory metastatic breast cancer (abstract 512) In: 8th NCI-EORTC Symp on New Drugs in Cancer Therapy: 1994 Ann Oncol 5 203-203

[4] Ten Bokkel Huinink WW(1994)Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers Eur J of Cancer 30A 1002-1007

[5] Prove AM(2001)Prediction of chemotherapeutic response by Technetium 99m-MIBI scintigraphy in breast carcinoma patients Cancer 92 232-239

[6] Piccart M(1997)Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes J Clin Invest 100 1282-1293

[7] Steward W(1994)Partial synthesis of major human metabolites of decetaxel Tetrahedron 50 10289-10298

[8] Tursz T(2002)Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues Int J Cancer 97 129-132

[9] Wanders J(1999)MGMT- and P450 3A-inhibitors do not sensitize glioblastoma cell cultures against nitrosoureas Clin Neuropathol 18 1-8

[10] Ravdin PM(1999)Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice Clin Cancer Res 5 883-889